Prog Retin Eye Res:NAD +和sirtuins在视网膜退行性疾病中的作用

2018-06-25 cuiguizhong MedSci原创

美国华盛顿大学眼科与视觉科学系的Lin JB近日在Prog Retin Eye Res发表了一篇综述文章,系统性的讨论了NAD +和sirtuins在调节视网膜代谢和视网膜退行性疾病发病中的作用。

美国华盛顿大学眼科与视觉科学系的Lin JB近日在Prog Retin Eye Res发表了一篇综述文章,系统性的讨论了NAD +和sirtuins在调节视网膜代谢和视网膜退行性疾病发病中的作用。

视网膜退行性疾病是现代社会造成视力损伤的主要发病原因,给患者造成明显的生活质量下降。治疗视网膜退行性疾病的一个重大挑战是其遗传因素和表型的异质性。尽管存在多样性,许多这些疾病共同的结局都涉及光敏感光受体的死亡。发现导致这些多种疾病中的光感受器死亡的常见致病机制可能会实现对多种视网膜疾病的统一治疗。这具有高度的创新性,并且可以满足极大的临床需求。

由于视网膜和光感受器具有活跃的代谢和巨大能量需求,因此许多研究者提出假设认为,代谢功能障碍可能是各种视网膜退行性疾病的常见致病机制。在这里,他们讨论了一个新的研究领域,研究NAD +和sirtuins在调节视网膜代谢和视网膜退行性疾病发病中的作用。事实上,许多研究的结果表明,NAD +中间体或调节sirtuin功能的小分子可以增强视网膜代谢,减少光感受器死亡,并改善视力。

因此他们认为,研究NAD +和sirtuins在调节视网膜代谢和视网膜退行性疾病发病中的作用具有很大的潜力,或许可以改变视网膜退行性疾病患者的治疗标准,但将这些发现转化为临床实践仍需要进一步研究。

原文出处:

Lin, J.B. and R.S. Apte, NAD(+) and sirtuins in retinal degenerative diseases: A look at future therapies. Prog Retin Eye Res, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1751710, encodeId=2bd11e51710f6, content=<a href='/topic/show?id=c7481635494' target=_blank style='color:#2F92EE;'>#Sirtuins#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16354, encryptionId=c7481635494, topicName=Sirtuins)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457836370764, createdName=huangdf, createdTime=Thu May 02 23:09:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913877, encodeId=922b19138e73f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Jul 19 16:09:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029855, encodeId=d0ac202985564, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Mon Jul 16 04:09:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735387, encodeId=1ace1e35387e9, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Sat Sep 15 04:09:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801615, encodeId=affc18016150e, content=<a href='/topic/show?id=961a90825ae' target=_blank style='color:#2F92EE;'>#视网膜退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90825, encryptionId=961a90825ae, topicName=视网膜退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Sep 01 05:09:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270071, encodeId=fda312e007177, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598497, encodeId=f5f8159849e01, content=<a href='/topic/show?id=829b124e643' target=_blank style='color:#2F92EE;'>#NAD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12476, encryptionId=829b124e643, topicName=NAD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b0018615070, createdName=pandamao2016, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602022, encodeId=2b911602022d0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327055, encodeId=fe1932e0558c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Jun 26 05:47:42 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327045, encodeId=de0f32e045b1, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jun 26 04:52:09 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2019-05-02 huangdf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1751710, encodeId=2bd11e51710f6, content=<a href='/topic/show?id=c7481635494' target=_blank style='color:#2F92EE;'>#Sirtuins#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16354, encryptionId=c7481635494, topicName=Sirtuins)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457836370764, createdName=huangdf, createdTime=Thu May 02 23:09:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913877, encodeId=922b19138e73f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Jul 19 16:09:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029855, encodeId=d0ac202985564, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Mon Jul 16 04:09:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735387, encodeId=1ace1e35387e9, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Sat Sep 15 04:09:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801615, encodeId=affc18016150e, content=<a href='/topic/show?id=961a90825ae' target=_blank style='color:#2F92EE;'>#视网膜退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90825, encryptionId=961a90825ae, topicName=视网膜退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Sep 01 05:09:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270071, encodeId=fda312e007177, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598497, encodeId=f5f8159849e01, content=<a href='/topic/show?id=829b124e643' target=_blank style='color:#2F92EE;'>#NAD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12476, encryptionId=829b124e643, topicName=NAD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b0018615070, createdName=pandamao2016, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602022, encodeId=2b911602022d0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327055, encodeId=fe1932e0558c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Jun 26 05:47:42 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327045, encodeId=de0f32e045b1, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jun 26 04:52:09 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-07-19 ysjykql
  3. [GetPortalCommentsPageByObjectIdResponse(id=1751710, encodeId=2bd11e51710f6, content=<a href='/topic/show?id=c7481635494' target=_blank style='color:#2F92EE;'>#Sirtuins#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16354, encryptionId=c7481635494, topicName=Sirtuins)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457836370764, createdName=huangdf, createdTime=Thu May 02 23:09:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913877, encodeId=922b19138e73f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Jul 19 16:09:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029855, encodeId=d0ac202985564, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Mon Jul 16 04:09:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735387, encodeId=1ace1e35387e9, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Sat Sep 15 04:09:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801615, encodeId=affc18016150e, content=<a href='/topic/show?id=961a90825ae' target=_blank style='color:#2F92EE;'>#视网膜退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90825, encryptionId=961a90825ae, topicName=视网膜退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Sep 01 05:09:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270071, encodeId=fda312e007177, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598497, encodeId=f5f8159849e01, content=<a href='/topic/show?id=829b124e643' target=_blank style='color:#2F92EE;'>#NAD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12476, encryptionId=829b124e643, topicName=NAD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b0018615070, createdName=pandamao2016, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602022, encodeId=2b911602022d0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327055, encodeId=fe1932e0558c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Jun 26 05:47:42 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327045, encodeId=de0f32e045b1, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jun 26 04:52:09 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1751710, encodeId=2bd11e51710f6, content=<a href='/topic/show?id=c7481635494' target=_blank style='color:#2F92EE;'>#Sirtuins#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16354, encryptionId=c7481635494, topicName=Sirtuins)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457836370764, createdName=huangdf, createdTime=Thu May 02 23:09:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913877, encodeId=922b19138e73f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Jul 19 16:09:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029855, encodeId=d0ac202985564, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Mon Jul 16 04:09:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735387, encodeId=1ace1e35387e9, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Sat Sep 15 04:09:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801615, encodeId=affc18016150e, content=<a href='/topic/show?id=961a90825ae' target=_blank style='color:#2F92EE;'>#视网膜退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90825, encryptionId=961a90825ae, topicName=视网膜退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Sep 01 05:09:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270071, encodeId=fda312e007177, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598497, encodeId=f5f8159849e01, content=<a href='/topic/show?id=829b124e643' target=_blank style='color:#2F92EE;'>#NAD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12476, encryptionId=829b124e643, topicName=NAD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b0018615070, createdName=pandamao2016, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602022, encodeId=2b911602022d0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327055, encodeId=fe1932e0558c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Jun 26 05:47:42 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327045, encodeId=de0f32e045b1, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jun 26 04:52:09 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1751710, encodeId=2bd11e51710f6, content=<a href='/topic/show?id=c7481635494' target=_blank style='color:#2F92EE;'>#Sirtuins#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16354, encryptionId=c7481635494, topicName=Sirtuins)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457836370764, createdName=huangdf, createdTime=Thu May 02 23:09:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913877, encodeId=922b19138e73f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Jul 19 16:09:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029855, encodeId=d0ac202985564, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Mon Jul 16 04:09:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735387, encodeId=1ace1e35387e9, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Sat Sep 15 04:09:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801615, encodeId=affc18016150e, content=<a href='/topic/show?id=961a90825ae' target=_blank style='color:#2F92EE;'>#视网膜退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90825, encryptionId=961a90825ae, topicName=视网膜退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Sep 01 05:09:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270071, encodeId=fda312e007177, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598497, encodeId=f5f8159849e01, content=<a href='/topic/show?id=829b124e643' target=_blank style='color:#2F92EE;'>#NAD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12476, encryptionId=829b124e643, topicName=NAD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b0018615070, createdName=pandamao2016, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602022, encodeId=2b911602022d0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327055, encodeId=fe1932e0558c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Jun 26 05:47:42 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327045, encodeId=de0f32e045b1, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jun 26 04:52:09 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1751710, encodeId=2bd11e51710f6, content=<a href='/topic/show?id=c7481635494' target=_blank style='color:#2F92EE;'>#Sirtuins#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16354, encryptionId=c7481635494, topicName=Sirtuins)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457836370764, createdName=huangdf, createdTime=Thu May 02 23:09:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913877, encodeId=922b19138e73f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Jul 19 16:09:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029855, encodeId=d0ac202985564, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Mon Jul 16 04:09:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735387, encodeId=1ace1e35387e9, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Sat Sep 15 04:09:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801615, encodeId=affc18016150e, content=<a href='/topic/show?id=961a90825ae' target=_blank style='color:#2F92EE;'>#视网膜退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90825, encryptionId=961a90825ae, topicName=视网膜退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Sep 01 05:09:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270071, encodeId=fda312e007177, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598497, encodeId=f5f8159849e01, content=<a href='/topic/show?id=829b124e643' target=_blank style='color:#2F92EE;'>#NAD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12476, encryptionId=829b124e643, topicName=NAD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b0018615070, createdName=pandamao2016, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602022, encodeId=2b911602022d0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327055, encodeId=fe1932e0558c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Jun 26 05:47:42 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327045, encodeId=de0f32e045b1, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jun 26 04:52:09 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-27 zutt
  7. [GetPortalCommentsPageByObjectIdResponse(id=1751710, encodeId=2bd11e51710f6, content=<a href='/topic/show?id=c7481635494' target=_blank style='color:#2F92EE;'>#Sirtuins#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16354, encryptionId=c7481635494, topicName=Sirtuins)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457836370764, createdName=huangdf, createdTime=Thu May 02 23:09:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913877, encodeId=922b19138e73f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Jul 19 16:09:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029855, encodeId=d0ac202985564, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Mon Jul 16 04:09:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735387, encodeId=1ace1e35387e9, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Sat Sep 15 04:09:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801615, encodeId=affc18016150e, content=<a href='/topic/show?id=961a90825ae' target=_blank style='color:#2F92EE;'>#视网膜退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90825, encryptionId=961a90825ae, topicName=视网膜退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Sep 01 05:09:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270071, encodeId=fda312e007177, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598497, encodeId=f5f8159849e01, content=<a href='/topic/show?id=829b124e643' target=_blank style='color:#2F92EE;'>#NAD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12476, encryptionId=829b124e643, topicName=NAD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b0018615070, createdName=pandamao2016, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602022, encodeId=2b911602022d0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327055, encodeId=fe1932e0558c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Jun 26 05:47:42 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327045, encodeId=de0f32e045b1, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jun 26 04:52:09 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-27 pandamao2016
  8. [GetPortalCommentsPageByObjectIdResponse(id=1751710, encodeId=2bd11e51710f6, content=<a href='/topic/show?id=c7481635494' target=_blank style='color:#2F92EE;'>#Sirtuins#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16354, encryptionId=c7481635494, topicName=Sirtuins)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457836370764, createdName=huangdf, createdTime=Thu May 02 23:09:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913877, encodeId=922b19138e73f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Jul 19 16:09:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029855, encodeId=d0ac202985564, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Mon Jul 16 04:09:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735387, encodeId=1ace1e35387e9, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Sat Sep 15 04:09:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801615, encodeId=affc18016150e, content=<a href='/topic/show?id=961a90825ae' target=_blank style='color:#2F92EE;'>#视网膜退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90825, encryptionId=961a90825ae, topicName=视网膜退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Sep 01 05:09:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270071, encodeId=fda312e007177, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598497, encodeId=f5f8159849e01, content=<a href='/topic/show?id=829b124e643' target=_blank style='color:#2F92EE;'>#NAD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12476, encryptionId=829b124e643, topicName=NAD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b0018615070, createdName=pandamao2016, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602022, encodeId=2b911602022d0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327055, encodeId=fe1932e0558c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Jun 26 05:47:42 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327045, encodeId=de0f32e045b1, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jun 26 04:52:09 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-27 sunylz
  9. [GetPortalCommentsPageByObjectIdResponse(id=1751710, encodeId=2bd11e51710f6, content=<a href='/topic/show?id=c7481635494' target=_blank style='color:#2F92EE;'>#Sirtuins#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16354, encryptionId=c7481635494, topicName=Sirtuins)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457836370764, createdName=huangdf, createdTime=Thu May 02 23:09:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913877, encodeId=922b19138e73f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Jul 19 16:09:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029855, encodeId=d0ac202985564, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Mon Jul 16 04:09:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735387, encodeId=1ace1e35387e9, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Sat Sep 15 04:09:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801615, encodeId=affc18016150e, content=<a href='/topic/show?id=961a90825ae' target=_blank style='color:#2F92EE;'>#视网膜退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90825, encryptionId=961a90825ae, topicName=视网膜退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Sep 01 05:09:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270071, encodeId=fda312e007177, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598497, encodeId=f5f8159849e01, content=<a href='/topic/show?id=829b124e643' target=_blank style='color:#2F92EE;'>#NAD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12476, encryptionId=829b124e643, topicName=NAD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b0018615070, createdName=pandamao2016, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602022, encodeId=2b911602022d0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327055, encodeId=fe1932e0558c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Jun 26 05:47:42 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327045, encodeId=de0f32e045b1, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jun 26 04:52:09 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-26 yjs木玉

    好好好好好好好好

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1751710, encodeId=2bd11e51710f6, content=<a href='/topic/show?id=c7481635494' target=_blank style='color:#2F92EE;'>#Sirtuins#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16354, encryptionId=c7481635494, topicName=Sirtuins)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457836370764, createdName=huangdf, createdTime=Thu May 02 23:09:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913877, encodeId=922b19138e73f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Jul 19 16:09:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029855, encodeId=d0ac202985564, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Mon Jul 16 04:09:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735387, encodeId=1ace1e35387e9, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Sat Sep 15 04:09:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801615, encodeId=affc18016150e, content=<a href='/topic/show?id=961a90825ae' target=_blank style='color:#2F92EE;'>#视网膜退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90825, encryptionId=961a90825ae, topicName=视网膜退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Sep 01 05:09:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270071, encodeId=fda312e007177, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598497, encodeId=f5f8159849e01, content=<a href='/topic/show?id=829b124e643' target=_blank style='color:#2F92EE;'>#NAD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12476, encryptionId=829b124e643, topicName=NAD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b0018615070, createdName=pandamao2016, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602022, encodeId=2b911602022d0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 27 14:09:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327055, encodeId=fe1932e0558c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Jun 26 05:47:42 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327045, encodeId=de0f32e045b1, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jun 26 04:52:09 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-26 1dd8c52fm63(暂无匿称)

    学习学习.继续关注

    0

相关资讯

Neurobiol Aging:孔庆鹏课题组揭示长寿老人能量代谢状况优于普通老人的机制

长寿老人(特别是百岁老人)往往能逃脱或延缓常见衰老相关疾病的困扰,其后代发生老年疾病的概率也要显着低于一般人群。因此,健康长寿老人及其后代往往被视作健康衰老的理想模型,基于该模型深入解析其健康长寿的遗传机理,将可能为老年疾病的防治和干预提供全新的视角和机遇。中国科学院昆明动物研究所孔庆鹏课题组与海南医学院教授蔡望伟实验室的前期合作研究发现:长寿老人的能量代谢状况要显着优于普通老年人群(He et

PLoS One: 房颤电复律后,SLC25A20和PDK4基因表达下降

背景:心房颤动(AF)患者恢复窦性心律治疗的长期成功率有限。基因表达谱可能为房颤的病理生理机制提供新的视野。目的:比较电复律(ECV)前后全血基因表达,了解AF的病理生理机制,识别生物标记物。方法:46例进行ECV的持续性房颤患者,复律前1-2小时,及复律成功后4至6周,收集全血标本。检测配对样品的微阵列和血浆生物标志物。结果:测试的13942个基因中,对SLC25A20和PDK4高表达与房颤相关

Diabetes:郭非凡等揭示亮氨酸缺乏时中枢神经系统调节外周能量代谢的新机制

近日,国际学术期刊Diabetes在线发表了上海生科院营养所郭非凡研究组的研究论文 “ S6K1 in the CNS regulates energy expenditure via MC4R/CRH pathways in response to deprivation of an essential amino acid ”。该研究首次发现下丘脑核糖体S6K蛋白激酶 (p70 S6K1)通过

Endocrinology:PAQR3在肥胖中的调控功能

中科院上海生科院营养所陈雁研究组在一项研究中,发现并阐明了一个能够调节机体肥胖的关键分子。近日,相关研究论文在线发表于《内分泌学》。【原文下载】 在研究员陈雁的指导下,博士生王玲娣等深入研究了在细胞内高尔基体特异定位蛋白质PAQR3的基因缺失对高脂饮食诱导小鼠发生肥胖、肝脏脂肪变性和胰岛素抵抗等改变的影响。 研究发现,PAQR3基因缺失的小鼠可以抵抗高脂饮食诱导产生的肥胖和肝脏脂肪变性

BMC Complement Altern Med:电针内关穴对心包经及所系脏腑能量代谢的影响

研究背景: 电针是在中医经络理论指导下的一种传统治疗手段。由于其在世界范围内得到了广泛认可,对于其机制的研究正逐步深入。然而,由于东西方医学存在巨大差异,很难用基于解剖和生理的现代医学理论来阐释经络的机制。早在两千多年前的中医古籍中就有对于经络内联脏腑,外络肢节的描述,而这一理论在临床实践中也得到了有效的验证。针刺治疗时经络发生的变化和对应的脏腑功能所发生的改变以及它们之间是否存在密切的联系成为

杨水祥:心力衰竭与心肌能量代谢

摘要:心肌能量代谢障碍是心力衰竭发生发展的病理生理原因之一。急性缺血缺氧使能量代谢发生改变,但起关键作用的是心脏能量代谢重构。本文将综述这方面的进展。 关键词:心力衰竭:心肌能量代谢 引言:心脏是特殊的Ⅰ型横纹肌组织,它的能量供应主要由有氧代谢供应。正常人体在静息状态下,心脏可以利用冠脉循环中60-65%的O2,氧利用率约是每克心肌4.5μmol/min,运动时可达3-4倍。生理情况下,心肌对